Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535191 | 0.98 | KDM4E (0.35) | KDM4EPOLBALDH1A1SMYD2CYP3A4 | |
| SCHEMBL535190 | 0.97 | KDM4E (0.34) | KDM4EPOLBALDH1A1SMYD2CYP3A4 | |
| SCHEMBL2955809 | 0.83 | SMYD2 (0.33) | KDM4EPOLBSMYD2CYP3A4HTT | |
| SCHEMBL3856318 | 0.83 | DGAT1 (0.35) | KDM4EPOLBSMYD2CYP3A4HTT | |
| SCHEMBL8027742 | 0.83 | SMYD2 (0.33) | KDM4EPOLBSMYD2CYP3A4HTT | |
| SCHEMBL17839109 | 0.81 | SMYD2 (0.34) | ALDH1A1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18748478 | 0.81 | NR1H2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17839089 | 0.81 | NR1H2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL8168666 | 0.79 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30563707 | 0.79 | SMYD2 (0.36) | ALDH1A1SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024153119-A1 | KRAS G12D INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-07-25 | — | — | WO | disclosed |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20180271824-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2018-09-27 | — | — | US | disclosed |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9693989-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-8648087-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2231614-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2185518-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| EP-1971601-B1 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-2090575-A1 | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | Array Biopharma, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009087098-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009030467-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG, (CH) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271824-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | KDM4E 1102/4885POLB 1028/4885ALDH1A1 2975/4885 |
| US-20140023643-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | KDM4E 4403/4885POLB 4441/4885ALDH1A1 109/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-10780073-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | KDM4E 1254/4885POLB 944/4885ALDH1A1 2816/4885 |
| US-20100280068-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A1, CYP3A7, CYP1A2 | KDM4E 1036/4885POLB 4575/4885ALDH1A1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.